TrialMedical oncology (Northwood, London, England)2014

Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.

Kai Wei et al.PubMed ↗Publisher ↗

No numbers read from the abstract.